CYP19A1 and polycystic ovary syndrome: Letrozole, a type of aromatase inhibitor that is not derived from steroids, possesses the capability of reducing estrogen levels while simultaneously boosting the production of endogenous androgens, grounded on the discovery that genetic variations in Cyp19a1 are linked to PCOS in females, while also disrupting the LH/FSH ratio (17).